PET/CT Molecular Imaging of Angiogenesis in Pulmonary or Head and Neck Cancers Prior to or During Chemotherapy Including Agent With Antiangiogenic Effect. A Prospective Multicentric Study of Efficacy and Tolerability.

The primary objective of this Phase II study is to evaluate the use of labelled RGD ligand in PET/CT to predict and/or to early assess the efficacy of chemotherapy including an agent with antiangiogenic effect.
The predictive value of this approach will be determined by independent assessors on basis of data at the end of the treatment: RECIST 1.1 criteria for CT or MRI, PERCIST criteria for FDG PET/CT, clinical, endoscopic and histological findings.

Start Date20 Mar 2015

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

100 Clinical Results associated with Flotegatide-F18

100 Translational Medicine associated with Flotegatide-F18

100 Patents (Medical) associated with Flotegatide-F18

Literatures (Medical) associated with Flotegatide-F18

01 Jun 2014·Journal of Nuclear CardiologyQ3 · MEDICINE

Atherosclerotic plaque uptake of a novel integrin tracer 18F-Flotegatide in a mouse model of atherosclerosis

Q3 · MEDICINE

Article

Author: Fanrong Mu ; Helen Su ; Hartmuth C. Kolb ; Gang Chen ; Balaji K. Tamarappoo ; Katrin Szardenings ; Joseph C. Walsh ; Umesh B. Gangadharmath ; Natalia Gorodny ; Luis Felipe Gomez ; Daniel S. Berman

INTRODUCTIONRupture of unstable atherosclerotic plaque that leads to stroke and myocardial infarction may be induced by macrophage infiltration and neovessel formation. A tracer that selectively binds to integrin αvβ3 a protein expressed by macrophages and neovascular endothelium may identify rupture prone plaque.METHODS(18)F-labeled "R-G-D" containing tripeptide (Flotegatide), a click chemistry derived radiotracer that binds to integrin αvβ3 was injected in ApoE knockout mice fed a high fat diet. Uptake of Flotegatide by atherosclerotic plaque was visualized by micro-PET, autoradiography, and correlated to histologic markers of inflammation and angiogenesis.RESULTSWe found that Flotegatide preferentially binds to aortic plaque in an ApoE knockout mouse model of atherosclerosis. The tracer's uptake is strongly associated with presence of histologic markers for macrophage infiltration and integrin expression. There is a weaker but detectable association between Flotegatide uptake and presence of an immunohistochemical marker for neovascularization.DISCUSSIONWe hypothesize that Flotegatide may be a useful tracer for visualization of inflamed plaque in clinical subjects with atherosclerosis and may have potential for detecting vulnerable plaque.

100 Deals associated with Flotegatide-F18

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Carotid Stenosis	Phase 2	US	Siemens Molecular Imaging, Inc.	01 May 2012
Breast Cancer	Phase 2	US	Siemens Molecular Imaging, Inc.	01 Sep 2009
Non-Small Cell Lung Cancer	Phase 2	US	Siemens Molecular Imaging, Inc.	01 Sep 2009
Glioma	Phase 2	US	Siemens Molecular Imaging, Inc.	01 Aug 2008
Melanoma	Phase 2	US	Siemens Molecular Imaging, Inc.	01 Aug 2008
Sarcoma	Phase 2	US	Siemens Molecular Imaging, Inc.	01 Aug 2008
Atherosclerosis	Phase 2	US	Siemens Molecular Imaging, Inc.	-
Neoplasms	Phase 2	FR	Assistance Publique des Hôpitaux de Paris SA	-
Colorectal Cancer	Discovery	US	Siemens Molecular Imaging, Inc.	01 Sep 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Flotegatide-F18

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation